Tricerri A, Vangeli M, Addario C, Guidi L, Bartoloni C, Magalini S, Gentiloni Silveri N
Istituto di Medicina Interna e Geriatria, Universitä Cattolica del Sacro Cuore, Roma, Italy.
Panminerva Med. 1997 Mar;39(1):64-6.
Rifampin is a drug able to induce adverse reactions involving both the kidney and the hematological system. We observed a case, throughly studied and we deemed worth-while to report it, for some important features that were evident. Transient hemolytic anemia, recoverable acute renal failure, persistent increased titer of anti-platelet antibody lasting also after 3 weeks from the withdrawal of the drug and in spite of corticosteroid therapy, could be explained by the immune mechanisms that are, therefore, postulated.